Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Stomatology Hospital of Guangzhou Medical University, Guangzhou 510140, China; Institute of Radiation and Polymer Technology, Bangladesh Atomic Energy Commission, Dhaka 1000, Bangladesh.
Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou 350117, China.
Acta Biomater. 2021 Sep 1;131:493-507. doi: 10.1016/j.actbio.2021.06.016. Epub 2021 Jun 15.
This study first reports the development of a smart drug delivery system (DDS) for multimodal synergistic cancer therapy combining chemo-photothermal-starvation approaches. A magnetic photothermal agent was synthesized by preparing iron oxide (IO) nanoparticles (NPs) with covalently attached indocyanine green (ICG) and glucose oxidase (GOx) (ICGOx@IO). Synthesized ICGOx@IO NPs were co-encapsulated with doxorubicin (Dox) and EGCG ((-)-epigallocatechin-3-gallate) inside PLGA (poly(lactic-co-glycolic acid)) NPs using multiple emulsion solvent evaporation method. Such formulation gave the advantage of triggered drug release by near-infrared (NIR) laser irradiation (808 nm at 1 W/cm). RGD peptide was attached to the surface of PLGA NPs and the final hydrodynamic size was around 210 nm. Dual targeting by peptide and 240 mT external magnet significantly improved cellular uptake. Cellular uptake was observed using FACS, electron and optical microscopy. Dual targeting along with laser irradiation could reduce in vitro cell viability by 90 ± 2% (Dox-equivalent dose: 10 µg/ml) and complete tumor ablation was achieved in vivo due to synergetic therapeutic effect. Another attractive feature of the DDS was the significant reduction of cardiotoxicity of doxorubicin by EGCG. This new platform is thus expected to hold strong promise for future multimodal combination therapy of cancers. STATEMENT OF SIGNIFICANCE: Doxorubicin is one of the most studied and effective chemotherapeutic agents whose application is hindered due to its cardiotoxicity. In this study, we used (-)-Epigallocatechin-3-gallate (EGCG) to overcome that limitation. However, drug delivery to tumor sites with no/minimum accumulation in healthy organs is always challenging. Although peptide-based targeting is very popular, the effectiveness of receptor/ligand binding active targeting is sometimes questioned which motivated us to apply dual targeting approach. Multimodal therapies can exhibit synergistic effects and subsequently reduce the required dose of drug over monotherapy. We aimed to achieve chemo-photothermal-starvation combination therapy in this study and such achievement is yet to be reported. Our developed system also has the advantage of triggered drug release by near-infrared (NIR) laser irradiation.
本研究首次报道了一种结合化学-光热-饥饿疗法的多功能协同癌症治疗智能药物递送系统(DDS)的发展。通过制备氧化铁(IO)纳米粒子(NPs)并将其共价连接到吲哚菁绿(ICG)和葡萄糖氧化酶(GOx)上(ICGOx@IO),合成了磁性光热剂。通过多重乳液溶剂蒸发法,将合成的 ICGOx@IO NPs 与阿霉素(Dox)和 EGCG((-)-表没食子儿茶素-3-没食子酸酯)共包封在 PLGA(聚乳酸-共-乙醇酸) NPs 内。这种制剂通过近红外(NIR)激光照射(808nm,1W/cm)具有触发药物释放的优势。RGD 肽被连接到 PLGA NPs 的表面,最终水动力直径约为 210nm。肽和 240mT 外磁场的双重靶向显著提高了细胞摄取。使用 FACS、电子和光学显微镜观察细胞摄取。激光照射协同双重靶向可将体外细胞活力降低 90%±2%(Dox 等效剂量:10μg/ml),并因协同治疗效果而实现完全肿瘤消融。DDS 的另一个吸引人的特点是 EGCG 显著降低了阿霉素的心脏毒性。因此,该新平台有望为癌症的未来多模式联合治疗提供强有力的前景。
阿霉素是研究最多和最有效的化疗药物之一,但由于其心脏毒性,其应用受到限制。在这项研究中,我们使用(-)-表没食子儿茶素-3-没食子酸酯(EGCG)克服了这一限制。然而,将药物递送到肿瘤部位而不在健康器官中最小化积累始终是一个挑战。尽管基于肽的靶向非常流行,但受体/配体结合的主动靶向的有效性有时会受到质疑,这促使我们应用双重靶向方法。多模式治疗可以表现出协同效应,从而减少单药治疗所需的药物剂量。在本研究中,我们旨在实现化学-光热-饥饿联合治疗,而这种成就尚未有报道。我们开发的系统还具有通过近红外(NIR)激光照射触发药物释放的优势。